PTC Therapeutics (PTCT) PT Raised to $82 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts PTCT Hot Sheet
Price: $62.09 +1.67%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 8 | New: 3
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 8 | New: 3
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $82.00 (from $70.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Vaisala OYJ (VAIAS:FH) (VAIAF) PT Raised to EUR63 at Berenberg
- Canaccord Downgrades Botanix Pharmaceuticals Ltd (BOT:AU) to Hold
- Asbury Automotive Group (ABG) PT Lowered to $232 at BofA Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
